Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
NeuroPair
AddedMar 20, 2024
UpdatedJun 18, 2026
NeuroPair

NeuroPair

NeuroPair: Restoring spinal cord function

HQ
Princeton, NJ, US
Overview
Compare
Fundraising
Employees
Website

NeuroPair, founded with the mission to restore spinal cord function, focuses on innovative treatments for spinal cord injuries. Their core product, Fibermag, is a pioneering approach that protects and guides the body’s tissue to regenerate lost function. This minimally invasive solution aims to offer a fast and versatile treatment option for patients suffering from spinal cord injuries. NeuroPair is dedicated to advancing medical science in this niche, targeting a critical market need with their cutting-edge technology.

Notable figures affiliated with NeuroPair include leading biomedical researchers and clinicians who bring valuable expertise to the company. The startup has garnered attention from key investors in the medical and biotech sectors, reflecting confidence in its potential impact. NeuroPair's achievements include significant progress in preclinical trials, positioning them as a promising player in the field of spinal cord injury treatment. Their work has the potential to revolutionize patient outcomes and set new standards in regenerative medicine.

NeuroPair - Similar Companies

Spinex logo

Spinex

spinex.co

NeuraMedica logo

NeuraMedica

Proneuron Biotechnologies logo

Proneuron Biotechnologies

proneuron.com

Neuraly logo

Neuraly

neuralymed.com

Neuraptive Therapeutics logo

Neuraptive Therapeutics

neuraptive.com

Neuro42 logo

Neuro42

Neuvotion logo

Neuvotion

neuvotion-inc.com

Epic Neuro logo

Epic Neuro

NeuRx Medical logo

NeuRx Medical

neurxmed.com

Neuright logo

Neuright

neurightlabs.com

NeuroCytonix logo

NeuroCytonix

neurocytonix.com

NeuroBionics logo

NeuroBionics

Innervace logo

Innervace

innervace.com

Neurolutions logo

Neurolutions

neurolutions.com

Progressive Nuero logo

Progressive Nuero

NeuroPair - Quick Facts

Who are NeuroPair's competitors?

Companies similar to NeuroPair include Spinex, NeuraMedica, Proneuron Biotechnologies and Neuraly.

Where is NeuroPair's headquarters located?

NeuroPair's headquarters is located in Princeton, NJ, US.

When was NeuroPair's last funding round?

NeuroPair's most recent funding round was for $150k (USD) in August 2022.

How much has NeuroPair raised to-date?

As of Aug 2, 2022, NeuroPair has raised a total of $150k (USD).

How many employees does NeuroPair have?

NeuroPair has 5 employees as of Feb 5, 2024.

NeuroPair - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified